A generic social post comparing the two drugs for weight loss and pointing to the head-to-head SURMOUNT-5 results. Nothing new beyond the trial itself.
Recap by typeshit. Post by Facebook on Facebook.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A comparison of how the investigational drug retatrutide stacks up on weight loss against existing obesity treatments.
Patients who got Revita after stopping tirzepatide regained 5.1% of body weight versus 8.2% on sham, yet Fractyl shares fell as investors judged the benefit small.
Loading…